Excelsior Biopharma Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 155.31 million compared to TWD 325.33 million a year ago. Net loss was TWD 12.45 million compared to TWD 2.91 million a year ago. Basic loss per share from continuing operations was TWD 0.27 compared to TWD 0.06 a year ago. Diluted loss per share from continuing operations was TWD 0.27 compared to TWD 0.06 a year ago.
For the six months, sales was TWD 328.96 million compared to TWD 670.69 million a year ago. Net loss was TWD 22.57 million compared to TWD 0.339 million a year ago. Basic loss per share from continuing operations was TWD 0.49 compared to TWD 0.01 a year ago. Diluted loss per share from continuing operations was TWD 0.49 compared to TWD 0.01 a year ago.